| Year |
Citation |
Score |
| 2023 |
Ajetunmobi OH, Wall G, Vidal Bonifacio B, Martinez Delgado LA, Chaturvedi AK, Najvar LK, Wormley FL, Patterson HP, Wiederhold NP, Patterson TF, Lopez-Ribot JL. High-Throughput Screening of the Repurposing Hub Library to Identify Drugs with Novel Inhibitory Activity against and Biofilms. Journal of Fungi (Basel, Switzerland). 9. PMID 37754987 DOI: 10.3390/jof9090879 |
0.358 |
|
| 2023 |
Ajetunmobi OH, Chaturvedi AK, Badali H, Vaccaro A, Najvar L, Wormley FL, Wiederhold NP, Patterson TF, Lopez-Ribot JL. Screening the medicine for malaria venture's Pandemic Response Box to identify novel inhibitors of Candida albicans and Candida auris biofilm formation. Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. PMID 37337909 DOI: 10.1111/apm.13342 |
0.339 |
|
| 2023 |
Ajetunmobi OH, Badali H, Romo JA, Ramage G, Lopez-Ribot JL. Antifungal therapy of biofilms: Past, present and future. Biofilm. 5: 100126. PMID 37193227 DOI: 10.1016/j.bioflm.2023.100126 |
0.308 |
|
| 2023 |
Ajetunmobi OH, Wall G, Bonifacio BV, Montelongo-Jauregui D, Lopez-Ribot JL. A 384-Well Microtiter Plate Model for Candida Biofilm Formation and Its Application to High-Throughput Screening. Methods in Molecular Biology (Clifton, N.J.). 2658: 53-64. PMID 37024695 DOI: 10.1007/978-1-0716-3155-3_5 |
0.359 |
|
| 2023 |
Ramage G, Borghi E, Rodrigues CF, Kean R, Williams C, Lopez-Ribot J. Our current clinical understanding of Candida biofilms: where are we two decades on? Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. PMID 36932821 DOI: 10.1111/apm.13310 |
0.317 |
|
| 2021 |
Cheng T, Torres NS, Chen P, Srinivasan A, Cardona S, Lee GC, Leung KP, Lopez-Ribot JL, Ramasubramanian AK. A Facile High-Throughput Model of Surface-Independent Staphylococcus aureus Biofilms by Spontaneous Aggregation. Msphere. 6. PMID 33910992 DOI: 10.1128/mSphere.00186-21 |
0.562 |
|
| 2020 |
Wall G, Chen E, Hull MV, Lopez-Ribot JL. Screening the CALIBR ReFRAME Library in Search for Inhibitors of Biofilm Formation. Frontiers in Cellular and Infection Microbiology. 10: 597931. PMID 33324579 DOI: 10.3389/fcimb.2020.597931 |
0.345 |
|
| 2020 |
Vazquez-Munoz R, Arellano-Jimenez MJ, Lopez-Ribot JL. Bismuth nanoparticles obtained by a facile synthesis method exhibit antimicrobial activity against and . Bmc Biomedical Engineering. 2: 11. PMID 33073175 DOI: 10.1186/s42490-020-00044-2 |
0.759 |
|
| 2020 |
Lara HH, Lopez-Ribot JL. Inhibition of Mixed Biofilms of and Methicillin-Resistant by Positively Charged Silver Nanoparticles and Functionalized Silicone Elastomers. Pathogens (Basel, Switzerland). 9. PMID 32992727 DOI: 10.3390/pathogens9100784 |
0.421 |
|
| 2020 |
Vazquez-Munoz R, Lopez FD, Lopez-Ribot JL. Silver Nanoantibiotics Display Strong Antifungal Activity Against the Emergent Multidrug-Resistant Yeast Under Both Planktonic and Biofilm Growing Conditions. Frontiers in Microbiology. 11: 1673. PMID 32849347 DOI: 10.3389/Fmicb.2020.01673 |
0.801 |
|
| 2020 |
Vazquez-Munoz R, Lopez FD, Lopez-Ribot JL. Bismuth Nanoantibiotics Display Anticandidal Activity and Disrupt the Biofilm and Cell Morphology of the Emergent Pathogenic Yeast . Antibiotics (Basel, Switzerland). 9. PMID 32751405 DOI: 10.3390/Antibiotics9080461 |
0.806 |
|
| 2020 |
Wall G, Lopez-Ribot JL. Current Antimycotics, New Prospects, and Future Approaches to Antifungal Therapy. Antibiotics (Basel, Switzerland). 9. PMID 32722455 DOI: 10.3390/Antibiotics9080445 |
0.39 |
|
| 2020 |
Wall G, Lopez-Ribot JL. Screening Repurposing Libraries for the Identification of Drugs with Novel Antifungal Activity. Antimicrobial Agents and Chemotherapy. PMID 32660991 DOI: 10.1128/Aac.00924-20 |
0.385 |
|
| 2020 |
Mei Y, Jiang T, Zou Y, Wang Y, Zhou J, Li J, Liu L, Tan J, Wei L, Li J, Dai H, Peng Y, Zhang L, Lopez-Ribot JL, Shapiro RS, et al. FDA Approved Drug Library Screening Identifies Robenidine as a Repositionable Antifungal. Frontiers in Microbiology. 11: 996. PMID 32582050 DOI: 10.3389/Fmicb.2020.00996 |
0.454 |
|
| 2020 |
Vazquez-Munoz R, Arellano-Jimenez MJ, Lopez-Ribot JL. Fast, facile synthesis method for BAL-mediated PVP-bismuth nanoparticles. Methodsx. 7: 100894. PMID 32405464 DOI: 10.1016/J.Mex.2020.100894 |
0.751 |
|
| 2020 |
Lara HH, Ixtepan-Turrent L, Jose Yacaman M, Lopez-Ribot J. Inhibition of Biofilm Formation on Medical and Environmental Surfaces by Silver Nanoparticles. Acs Applied Materials & Interfaces. PMID 31944650 DOI: 10.1021/Acsami.9B20708 |
0.471 |
|
| 2020 |
Vazquez-Munoz R, Lopez-Ribot JL. Nanotechnology as an Alternative to Reduce the Spread of COVID-19 Challenges. 11: 15. DOI: 10.3390/Challe11020015 |
0.415 |
|
| 2020 |
Jagadesan P, Yu Z, Barboza-Ramos I, Lara HH, Vazquez-Munoz R, López-Ribot JL, Schanze KS. Light Activated Anti-Fungal Properties of Imidazolium Functionalized Cationic Conjugated Polymers Chemistry of Materials. 32: 6186-6196. DOI: 10.1021/Acs.Chemmater.0C02076 |
0.359 |
|
| 2019 |
Bonifácio BV, Vila TVM, Masiero IF, da Silva PB, da Silva IC, de Oliveira Lopes É, Dos Santos Ramos MA, de Souza LP, Vilegas W, Pavan FR, Chorilli M, Lopez-Ribot JL, Bauab TM. Antifungal Activity of a Hydroethanolic Extract From Leaves Against and . Frontiers in Microbiology. 10: 2642. PMID 31803166 DOI: 10.3389/Fmicb.2019.02642 |
0.344 |
|
| 2019 |
Vazquez-Muñoz R, Arellano-Jimenez MJ, Lopez FD, Lopez-Ribot JL. Protocol optimization for a fast, simple and economical chemical reduction synthesis of antimicrobial silver nanoparticles in non-specialized facilities. Bmc Research Notes. 12: 773. PMID 31775864 DOI: 10.1186/S13104-019-4813-Z |
0.756 |
|
| 2019 |
Wall G, Herrera N, Lopez-Ribot JL. Repositionable Compounds with Antifungal Activity against Multidrug Resistant Identified in the Medicines for Malaria Venture's Pathogen Box. Journal of Fungi (Basel, Switzerland). 5. PMID 31581540 DOI: 10.3390/Jof5040092 |
0.362 |
|
| 2019 |
Montelongo-Jauregui D, Saville SP, Lopez-Ribot JL. Contributions of Candida albicans Dimorphism, Adhesive Interactions, and Extracellular Matrix to the Formation of Dual-Species Biofilms with Streptococcus gordonii. Mbio. 10. PMID 31213561 DOI: 10.1128/Mbio.01179-19 |
0.441 |
|
| 2019 |
Wall G, Montelongo-Jauregui D, Vidal Bonifacio B, Lopez-Ribot JL, Uppuluri P. Candida albicans biofilm growth and dispersal: contributions to pathogenesis. Current Opinion in Microbiology. 52: 1-6. PMID 31085405 DOI: 10.1016/J.Mib.2019.04.001 |
0.478 |
|
| 2019 |
Srinivasan A, Ramasubramanian AK, Lopez-Ribot JL. Nano-biofilm Arrays as a Novel Universal Platform for Microscale Microbial Culture and High-Throughput Downstream Applications. Current Medicinal Chemistry. PMID 30621556 DOI: 10.2174/0929867326666190107155953 |
0.625 |
|
| 2018 |
Torres NS, Montelongo-Jauregui D, Abercrombie JJ, Srinivasan A, Lopez-Ribot JL, Ramasubramanian AK, Leung KP. Antimicrobial and Antibiofilm Activity of Synergistic Combinations of a Commercially Available Small Compound Library With Colistin Against . Frontiers in Microbiology. 9: 2541. PMID 30410476 DOI: 10.3389/Fmicb.2018.02541 |
0.613 |
|
| 2018 |
Montelongo-Jauregui D, Lopez-Ribot JL. Candida Interactions with the Oral Bacterial Microbiota. Journal of Fungi (Basel, Switzerland). 4. PMID 30400279 DOI: 10.3390/Jof4040122 |
0.361 |
|
| 2018 |
Dekkerová J, Lopez-Ribot JL, Bujdáková H. Activity of anti-CR3-RP polyclonal antibody against biofilms formed by Candida auris, a multidrug-resistant emerging fungal pathogen. European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. PMID 30327897 DOI: 10.1007/S10096-018-3400-X |
0.472 |
|
| 2018 |
Wall G, Chaturvedi AK, Wormley FL, Wiederhold NP, Patterson HP, Patterson TF, Lopez-Ribot JL. Screening a Repurposing Library for Inhibitors of Multi-Drug Resistant Identifies Ebselen as a Repositionable Candidate for Antifungal Drug Development. Antimicrobial Agents and Chemotherapy. PMID 30104269 DOI: 10.1128/Aac.01084-18 |
0.446 |
|
| 2018 |
Romo JA, Pierce CG, Esqueda M, Hung CY, Saville SP, Lopez-Ribot JL. Characterization of a Biaryl Amide Anti-virulence Compound Targeting Filamentation and Biofilm Formation. Frontiers in Cellular and Infection Microbiology. 8: 227. PMID 30042929 DOI: 10.3389/Fcimb.2018.00227 |
0.405 |
|
| 2018 |
Dijck PV, Sjollema J, Cammue BP, Lagrou K, Berman J, d'Enfert C, Andes DR, Arendrup MC, Brakhage AA, Calderone R, Cantón E, Coenye T, Cos P, Cowen LE, Edgerton M, ... ... Lopez-Ribot JL, et al. Methodologies for and evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. Microbial Cell (Graz, Austria). 5: 300-326. PMID 29992128 DOI: 10.15698/Mic2018.07.638 |
0.447 |
|
| 2018 |
Montelongo-Jauregui D, Srinivasan A, Ramasubramanian AK, Lopez-Ribot JL. An In Vitro Model for Biofilms on Titanium Surfaces. Journal of Fungi (Basel, Switzerland). 4. PMID 29866990 DOI: 10.3390/Jof4020066 |
0.61 |
|
| 2018 |
Lara HH, Guisbiers G, Mendoza J, Mimun LC, Vincent BA, Lopez-Ribot JL, Nash KL. Synergistic antifungal effect of chitosan-stabilized selenium nanoparticles synthesized by pulsed laser ablation in liquids against biofilms. International Journal of Nanomedicine. 13: 2697-2708. PMID 29760550 DOI: 10.2147/Ijn.S151285 |
0.49 |
|
| 2017 |
Romo JA, Pierce CG, Chaturvedi AK, Lazzell AL, McHardy SF, Saville SP, Lopez-Ribot JL. Development of Anti-Virulence Approaches for Candidiasis via a Novel Series of Small-Molecule Inhibitors of Candida albicans Filamentation. Mbio. 8. PMID 29208749 DOI: 10.1128/Mbio.01991-17 |
0.467 |
|
| 2017 |
Srinivasan A, Lee GC, Torres NS, Hernandez K, Dallas SD, Lopez-Ribot J, Frei CR, Ramasubramanian AK. High-throughput microarray for antimicrobial susceptibility testing. Biotechnology Reports (Amsterdam, Netherlands). 16: 44-47. PMID 29167758 DOI: 10.1016/J.Btre.2017.10.004 |
0.529 |
|
| 2017 |
Srinivasan A, Torres NS, Leung KP, Lopez-Ribot JL, Ramasubramanian AK. nBioChip, a Lab-on-a-Chip Platform of Mono- and Polymicrobial Biofilms for High-Throughput Downstream Applications. Msphere. 2. PMID 28680970 DOI: 10.1128/mSphere.00247-17 |
0.577 |
|
| 2017 |
Pierce CG, Vila T, Romo JA, Montelongo-Jauregui D, Wall G, Ramasubramanian A, Lopez-Ribot JL. The Candida albicans Biofilm Matrix: Composition, Structure and Function. Journal of Fungi (Basel, Switzerland). 3. PMID 28516088 DOI: 10.3390/Jof3010014 |
0.433 |
|
| 2016 |
Vila T, Lopez-Ribot JL. Screening the "Pathogen Box" for the Identification of Candida albicans Biofilm Inhibitors. Antimicrobial Agents and Chemotherapy. PMID 27795383 DOI: 10.1128/Aac.02006-16 |
0.485 |
|
| 2016 |
Torres NS, Abercrombie JJ, Srinivasan A, Lopez-Ribot JL, Ramasubramanian AK, Leung KP. Screening a Commercial Library of Pharmacologically Active Small Molecules Against Staphylococcus aureus Biofilms. Antimicrobial Agents and Chemotherapy. PMID 27401577 DOI: 10.1128/Aac.00377-16 |
0.611 |
|
| 2016 |
Wiederhold NP, Patterson TF, Srinivasan A, Chaturvedi AK, Fothergill AW, Wormley FL, Ramasubramanian AK, Lopez-Ribot JL. Repurposing Auranofin as an Antifungal: In Vitro Activity against a Variety of Medically Important Fungi. Virulence. 0. PMID 27268469 DOI: 10.1080/21505594.2016.1196301 |
0.569 |
|
| 2016 |
Vila T, Romo JA, Pierce CG, McHardy SF, Saville SP, Lopez-Ribot JL. Targeting Candida albicans filamentation for antifungal drug development. Virulence. 0. PMID 27268130 DOI: 10.1080/21505594.2016.1197444 |
0.43 |
|
| 2016 |
Montelongo-Jauregui D, Srinivasan A, Ramasubramanian AK, Lopez-Ribot JL. An In Vitro Model for Oral Mixed Biofilms of Candida albicans and Streptococcus gordonii in Synthetic Saliva. Frontiers in Microbiology. 7: 686. PMID 27242712 DOI: 10.3389/Fmicb.2016.00686 |
0.635 |
|
| 2016 |
Uppuluri P, Lopez-Ribot JL. Go Forth and Colonize: Dispersal from Clinically Important Microbial Biofilms. Plos Pathogens. 12: e1005397. PMID 26891125 DOI: 10.1371/Journal.Ppat.1005397 |
0.455 |
|
| 2016 |
Cleary IA, Reinhard SM, Lazzell AL, Monteagudo C, Thomas DP, Lopez-Ribot JL, Saville SP. Examination of the pathogenic potential of Candida albicans filamentous cells in an animal model of haematogenously disseminated candidiasis. Fems Yeast Research. 16. PMID 26851404 DOI: 10.1093/Femsyr/Fow011 |
0.431 |
|
| 2016 |
Montes M, Pierce CG, Lopez-Ribot JL, Bhalla AS, Guo R. Properties of silver and copper nanoparticle containing aqueous suspensions and evaluation of their in vitro activity against candida albicans and staphylococcus aureus biofilms Journal of Nano Research. 37: 109-121. DOI: 10.4028/Www.Scientific.Net/Jnanor.37.109 |
0.458 |
|
| 2015 |
Romero-Urbina DG, Lara HH, Velázquez-Salazar JJ, Arellano-Jiménez MJ, Larios E, Srinivasan A, Lopez-Ribot JL, Yacamán MJ. Ultrastructural changes in methicillin-resistant Staphylococcus aureus induced by positively charged silver nanoparticles. Beilstein Journal of Nanotechnology. 6: 2396-405. PMID 26734530 DOI: 10.3762/Bjnano.6.246 |
0.553 |
|
| 2015 |
Pierce CG, Chaturvedi AK, Lazzell AL, Powell AT, Saville SP, McHardy SF, Lopez-Ribot JL. A Novel Small Molecule Inhibitor of Candida albicans Biofilm Formation, Filamentation and Virulence with Low Potential for the Development of Resistance. Npj Biofilms and Microbiomes. 1. PMID 26691764 DOI: 10.1038/npjbiofilms.2015.12 |
0.319 |
|
| 2015 |
Lara HH, Romero-Urbina DG, Pierce C, Lopez-Ribot JL, Arellano-Jiménez MJ, Jose-Yacaman M. Effect of silver nanoparticles on Candida albicans biofilms: an ultrastructural study. Journal of Nanobiotechnology. 13: 91. PMID 26666378 DOI: 10.1186/S12951-015-0147-8 |
0.487 |
|
| 2015 |
Vila TV, Chaturvedi AK, Rozental S, Lopez-Ribot JL. Characterization of the in vitro activity of Miltefosine against Candida albicans under planktonic and biofilm growing conditions and in vivo efficacy in the murine model of oral candidiasis. Antimicrobial Agents and Chemotherapy. PMID 26416861 DOI: 10.1128/Aac.01890-15 |
0.507 |
|
| 2015 |
Actis L, Srinivasan A, Lopez-Ribot JL, Ramasubramanian AK, Ong JL. Effect of silver nanoparticle geometry on methicillin susceptible and resistant Staphylococcus aureus, and osteoblast viability. Journal of Materials Science. Materials in Medicine. 26: 215. PMID 26194976 DOI: 10.1007/S10856-015-5538-8 |
0.591 |
|
| 2015 |
Pierce CG, Srinivasan A, Ramasubramanian AK, López-Ribot JL. From Biology to Drug Development: New Approaches to Combat the Threat of Fungal Biofilms. Microbiology Spectrum. 3. PMID 26185082 DOI: 10.1128/Microbiolspec.Mb-0007-2014 |
0.629 |
|
| 2015 |
Srinivasan A, Lopez-Ribot JL, Ramasubramanian AK. Microscale microbial culture. Future Microbiology. 10: 143-6. PMID 25689525 DOI: 10.2217/Fmb.14.129 |
0.493 |
|
| 2014 |
Albataineh MT, Lazzell A, Lopez-Ribot JL, Kadosh D. Ppg1, a PP2A-type protein phosphatase, controls filament extension and virulence in Candida albicans. Eukaryotic Cell. 13: 1538-47. PMID 25326520 DOI: 10.1128/Ec.00199-14 |
0.362 |
|
| 2014 |
Lopez-Ribot JL. Large-scale biochemical profiling of the Candida albicans biofilm matrix: new compositional, structural, and functional insights. Mbio. 5: e01781-14. PMID 25205098 DOI: 10.1128/Mbio.01781-14 |
0.431 |
|
| 2014 |
Chaturvedi AK, Hameed RS, Wozniak KL, Hole CR, Leopold Wager CM, Weintraub ST, Lopez-Ribot JL, Wormley FL. Vaccine-mediated immune responses to experimental pulmonary Cryptococcus gattii infection in mice. Plos One. 9: e104316. PMID 25119981 DOI: 10.1371/Journal.Pone.0104316 |
0.3 |
|
| 2014 |
Srinivasan A, Lopez-Ribot JL, Ramasubramanian AK. Overcoming antifungal resistance. Drug Discovery Today. Technologies. 11: 65-71. PMID 24847655 DOI: 10.1016/J.Ddtec.2014.02.005 |
0.54 |
|
| 2014 |
Pierce CG, Saville SP, Lopez-Ribot JL. High-content phenotypic screenings to identify inhibitors of Candida albicans biofilm formation and filamentation. Pathogens and Disease. 70: 423-31. PMID 24623598 DOI: 10.1111/2049-632X.12161 |
0.481 |
|
| 2014 |
Sarkar S, Uppuluri P, Pierce CG, Lopez-Ribot JL. In vitro study of sequential fluconazole and caspofungin treatment against Candida albicans biofilms. Antimicrobial Agents and Chemotherapy. 58: 1183-6. PMID 24217700 DOI: 10.1128/Aac.01745-13 |
0.415 |
|
| 2014 |
Srinivasan A, Gupta CM, Agrawal CM, Leung KP, Lopez-Ribot JL, Ramasubramanian AK. Drug susceptibility of matrix-encapsulated Candida albicans nano-biofilms. Biotechnology and Bioengineering. 111: 418-24. PMID 24114441 DOI: 10.1002/Bit.25120 |
0.603 |
|
| 2013 |
Kadosh D, Lopez-Ribot JL. Candida albicans: adapting to succeed. Cell Host & Microbe. 14: 483-5. PMID 24237692 DOI: 10.1016/J.Chom.2013.10.016 |
0.312 |
|
| 2013 |
Pierce CG, Srinivasan A, Uppuluri P, Ramasubramanian AK, López-Ribot JL. Antifungal therapy with an emphasis on biofilms. Current Opinion in Pharmacology. 13: 726-30. PMID 24011516 DOI: 10.1016/J.Coph.2013.08.008 |
0.589 |
|
| 2013 |
Srinivasan A, Leung KP, Lopez-Ribot JL, Ramasubramanian AK. High-throughput nano-biofilm microarray for antifungal drug discovery. Mbio. 4. PMID 23800397 DOI: 10.1128/Mbio.00331-13 |
0.607 |
|
| 2013 |
Pierce CG, Lopez-Ribot JL. Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs. Expert Opinion On Drug Discovery. 8: 1117-26. PMID 23738751 DOI: 10.1517/17460441.2013.807245 |
0.403 |
|
| 2013 |
Siles SA, Srinivasan A, Pierce CG, Lopez-Ribot JL, Ramasubramanian AK. High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors. Antimicrobial Agents and Chemotherapy. 57: 3681-7. PMID 23689719 DOI: 10.1128/Aac.00680-13 |
0.584 |
|
| 2013 |
Banerjee M, Uppuluri P, Zhao XR, Carlisle PL, Vipulanandan G, Villar CC, López-Ribot JL, Kadosh D. Expression of UME6, a key regulator of Candida albicans hyphal development, enhances biofilm formation via Hgc1- and Sun41-dependent mechanisms. Eukaryotic Cell. 12: 224-32. PMID 23223035 DOI: 10.1128/Ec.00163-12 |
0.467 |
|
| 2012 |
Srinivasan A, Lopez-Ribot JL, Ramasubramanian AK. Candida albicans biofilm chip (CaBChip) for high-throughput antifungal drug screening. Journal of Visualized Experiments : Jove. e3845. PMID 22847237 DOI: 10.3791/3845 |
0.641 |
|
| 2012 |
Martins M, Henriques M, Lopez-Ribot JL, Oliveira R. Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilms. Mycoses. 55: 80-5. PMID 21668524 DOI: 10.1111/J.1439-0507.2011.02047.X |
0.492 |
|
| 2011 |
Chambers JP, Yu JJ, Jupelli M, Weintraub ST, Lopez-Ribot JL, Valdes JJ, Arulanandam BP. Alpha-1 antitrypsin is markedly decreased following pulmonary F. tularensis challenge. Frontiers in Cellular and Infection Microbiology. 1: 20. PMID 22919586 DOI: 10.3389/Fcimb.2011.00020 |
0.313 |
|
| 2011 |
Robbins N, Uppuluri P, Nett J, Rajendran R, Ramage G, Lopez-Ribot JL, Andes D, Cowen LE. Hsp90 governs dispersion and drug resistance of fungal biofilms. Plos Pathogens. 7: e1002257. PMID 21931556 DOI: 10.1371/Journal.Ppat.1002257 |
0.458 |
|
| 2011 |
Chaturvedi AK, Lazzell AL, Saville SP, Wormley FL, Monteagudo C, Lopez-Ribot JL. Validation of the tetracycline regulatable gene expression system for the study of the pathogenesis of infectious disease. Plos One. 6: e20449. PMID 21633704 DOI: 10.1371/Journal.Pone.0020449 |
0.366 |
|
| 2011 |
Srinivasan A, Uppuluri P, Lopez-Ribot J, Ramasubramanian AK. Development of a high-throughput Candida albicans biofilm chip. Plos One. 6: e19036. PMID 21544190 DOI: 10.1371/Journal.Pone.0019036 |
0.634 |
|
| 2011 |
Uppuluri P, Srinivasan A, Ramasubramanian A, Lopez-Ribot JL. Effects of fluconazole, amphotericin B, and caspofungin on Candida albicans biofilms under conditions of flow and on biofilm dispersion. Antimicrobial Agents and Chemotherapy. 55: 3591-3. PMID 21518839 DOI: 10.1128/Aac.01701-10 |
0.588 |
|
| 2010 |
Uppuluri P, Lopez-Ribot JL. An easy and economical in vitro method for the formation of Candida albicans biofilms under continuous conditions of flow. Virulence. 1: 483-7. PMID 21178492 DOI: 10.4161/Viru.1.6.13186 |
0.409 |
|
| 2010 |
Pierce CG, Uppuluri P, Tummala S, Lopez-Ribot JL. A 96 well microtiter plate-based method for monitoring formation and antifungal susceptibility testing of Candida albicans biofilms. Journal of Visualized Experiments : Jove. PMID 21048668 DOI: 10.3791/2287 |
0.495 |
|
| 2010 |
Uppuluri P, Pierce CG, Thomas DP, Bubeck SS, Saville SP, Lopez-Ribot JL. The transcriptional regulator Nrg1p controls Candida albicans biofilm formation and dispersion. Eukaryotic Cell. 9: 1531-7. PMID 20709787 DOI: 10.1128/Ec.00111-10 |
0.472 |
|
| 2010 |
Uppuluri P, Chaturvedi AK, Srinivasan A, Banerjee M, Ramasubramaniam AK, Köhler JR, Kadosh D, Lopez-Ribot JL. Dispersion as an important step in the Candida albicans biofilm developmental cycle. Plos Pathogens. 6: e1000828. PMID 20360962 DOI: 10.1371/Journal.Ppat.1000828 |
0.618 |
|
| 2010 |
Martins M, Uppuluri P, Thomas DP, Cleary IA, Henriques M, Lopez-Ribot JL, Oliveira R. Presence of extracellular DNA in the Candida albicans biofilm matrix and its contribution to biofilms. Mycopathologia. 169: 323-31. PMID 20012895 DOI: 10.1007/S11046-009-9264-Y |
0.44 |
|
| 2010 |
Ramage G, Mowat E, Jones B, Williams C, Lopez-Ribot J. Our current understanding of fungal biofilms. Critical Reviews in Microbiology. 35: 340-55. PMID 19863383 DOI: 10.3109/10408410903241436 |
0.455 |
|
| 2009 |
Uppuluri P, Pierce CG, López-Ribot JL. Candida albicans biofilm formation and its clinical consequences. Future Microbiology. 4: 1235-7. PMID 19995182 DOI: 10.2217/Fmb.09.85 |
0.519 |
|
| 2009 |
Thomas DP, Lopez-Ribot JL, Lee SA. A proteomic analysis of secretory proteins of a pre-vacuolar mutant of Candida albicans Journal of Proteomics. 73: 342-351. PMID 19819358 DOI: 10.1016/J.Jprot.2009.10.003 |
0.331 |
|
| 2009 |
Uppuluri P, Dinakaran H, Thomas DP, Chaturvedi AK, Lopez-Ribot JL. Characteristics of Candida albicans biofilms grown in a synthetic urine medium. Journal of Clinical Microbiology. 47: 4078-83. PMID 19794044 DOI: 10.1128/Jcm.01377-09 |
0.503 |
|
| 2009 |
Lazzell AL, Chaturvedi AK, Pierce CG, Prasad D, Uppuluri P, Lopez-Ribot JL. Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis. The Journal of Antimicrobial Chemotherapy. 64: 567-70. PMID 19584104 DOI: 10.1093/Jac/Dkp242 |
0.376 |
|
| 2009 |
Grubb SE, Murdoch C, Sudbery PE, Saville SP, Lopez-Ribot JL, Thornhill MH. Adhesion of Candida albicans to endothelial cells under physiological conditions of flow. Infection and Immunity. 77: 3872-8. PMID 19581400 DOI: 10.1128/Iai.00518-09 |
0.363 |
|
| 2009 |
Redding S, Bhatt B, Rawls HR, Siegel G, Scott K, Lopez-Ribot J. Inhibition of Candida albicans biofilm formation on denture material. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics. 107: 669-72. PMID 19426921 DOI: 10.1016/J.Tripleo.2009.01.021 |
0.397 |
|
| 2009 |
Uppuluri P, Chaturvedi AK, Lopez-Ribot JL. Design of a simple model of Candida albicans biofilms formed under conditions of flow: development, architecture, and drug resistance. Mycopathologia. 168: 101-9. PMID 19370400 DOI: 10.1007/S11046-009-9205-9 |
0.455 |
|
| 2009 |
Carlisle PL, Banerjee M, Lazzell A, Monteagudo C, López-Ribot JL, Kadosh D. Expression levels of a filament-specific transcriptional regulator are sufficient to determine Candida albicans morphology and virulence. Proceedings of the National Academy of Sciences of the United States of America. 106: 599-604. PMID 19116272 DOI: 10.1073/Pnas.0804061106 |
0.388 |
|
| 2009 |
Pierce CG, Thomas DP, López-Ribot JL. Effect of tunicamycin on Candida albicans biofilm formation and maintenance. The Journal of Antimicrobial Chemotherapy. 63: 473-9. PMID 19098294 DOI: 10.1093/Jac/Dkn515 |
0.471 |
|
| 2008 |
Lee SA, Jones J, Hardison S, Kot J, Khalique Z, Bernardo SM, Lazzell A, Monteagudo C, Lopez-Ribot J. Candida albicans VPS4 is required for secretion of aspartyl proteases and in vivo virulence. Mycopathologia. 167: 55-63. PMID 18814053 DOI: 10.1007/S11046-008-9155-7 |
0.375 |
|
| 2008 |
Pierce CG, Uppuluri P, Tristan AR, Wormley FL, Mowat E, Ramage G, Lopez-Ribot JL. A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nature Protocols. 3: 1494-500. PMID 18772877 DOI: 10.1038/Nport.2008.141 |
0.49 |
|
| 2008 |
Grubb SE, Murdoch C, Sudbery PE, Saville SP, Lopez-Ribot JL, Thornhill MH. Candida albicans-endothelial cell interactions: a key step in the pathogenesis of systemic candidiasis. Infection and Immunity. 76: 4370-7. PMID 18573891 DOI: 10.1128/Iai.00332-08 |
0.353 |
|
| 2008 |
Ramage G, Wickes BL, López-Ribot JL. A seed and feed model for the formation of Candida albicans biofilms under flow conditions using an improved modified Robbins device. Revista Iberoamericana De MicologíA. 25: 37-40. PMID 18338926 DOI: 10.1016/S1130-1406(08)70009-3 |
0.424 |
|
| 2008 |
Banerjee M, Thompson DS, Lazzell A, Carlisle PL, Pierce C, Monteagudo C, López-Ribot JL, Kadosh D. UME6, a novel filament-specific regulator of Candida albicans hyphal extension and virulence. Molecular Biology of the Cell. 19: 1354-65. PMID 18216277 DOI: 10.1091/Mbc.E07-11-1110 |
0.378 |
|
| 2008 |
Saville SP, Lazzell AL, Chaturvedi AK, Monteagudo C, Lopez-Ribot JL. Use of a genetically engineered strain to evaluate the pathogenic potential of yeast cell and filamentous forms during Candida albicans systemic infection in immunodeficient mice. Infection and Immunity. 76: 97-102. PMID 17967861 DOI: 10.1128/Iai.00982-07 |
0.356 |
|
| 2007 |
Ramage G, Wickes BL, López-Ribot JL. Inhibition on Candida albicans biofilm formation using divalent cation chelators (EDTA). Mycopathologia. 164: 301-6. PMID 17909983 DOI: 10.1007/S11046-007-9068-X |
0.472 |
|
| 2006 |
Thomas DP, Pitarch A, Monteoliva L, Gil C, Lopez-Ribot JL. Proteomics to study Candida albicans biology and pathogenicity. Infectious Disorders Drug Targets. 6: 335-41. PMID 17168799 DOI: 10.2174/187152606779025815 |
0.406 |
|
| 2006 |
Pérez A, Pedrós B, Murgui A, Casanova M, López-Ribot JL, Martínez JP. Biofilm formation by Candida albicans mutants for genes coding fungal proteins exhibiting the eight-cysteine-containing CFEM domain. Fems Yeast Research. 6: 1074-84. PMID 17042757 DOI: 10.1111/J.1567-1364.2006.00131.X |
0.371 |
|
| 2006 |
Ramage G, Martínez JP, López-Ribot JL. Candida biofilms on implanted biomaterials: a clinically significant problem. Fems Yeast Research. 6: 979-86. PMID 17042747 DOI: 10.1111/J.1567-1364.2006.00117.X |
0.448 |
|
| 2006 |
Saville SP, Lazzell AL, Bryant AP, Fretzen A, Monreal A, Solberg EO, Monteagudo C, Lopez-Ribot JL, Milne GT. Inhibition of filamentation can be used to treat disseminated candidiasis. Antimicrobial Agents and Chemotherapy. 50: 3312-6. PMID 17005810 DOI: 10.1128/Aac.00628-06 |
0.437 |
|
| 2006 |
Thomas DP, Bachmann SP, Lopez-Ribot JL. Proteomics for the analysis of the Candida albicans biofilm lifestyle. Proteomics. 6: 5795-804. PMID 17001605 DOI: 10.1002/Pmic.200600332 |
0.433 |
|
| 2006 |
Chamilos G, Lionakis MS, Lewis RE, Lopez-Ribot JL, Saville SP, Albert ND, Halder G, Kontoyiannis DP. Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. The Journal of Infectious Diseases. 193: 1014-22. PMID 16518764 DOI: 10.1086/500950 |
0.368 |
|
| 2005 |
Sánchez-Vargas LO, Ortiz-López NG, Villar M, Moragues MD, Aguirre JM, Cashat-Cruz M, Lopez-Ribot JL, Gaitán-Cepeda LA, Quindós G. Point prevalence, microbiology and antifungal susceptibility patterns of oral Candida isolates colonizing or infecting Mexican HIV/AIDS patients and healthy persons. Revista Iberoamericana De MicologíA. 22: 83-92. PMID 16107165 DOI: 10.1016/S1130-1406(05)70014-0 |
0.348 |
|
| 2005 |
Sánchez-Vargas LO, Ortiz-López NG, Villar M, Moragues MD, Aguirre JM, Cashat-Cruz M, Lopez-Ribot JL, Gaitán-Cepeda LA, Quindós G. Oral Candida isolates colonizing or infecting human immunodeficiency virus-infected and healthy persons in Mexico. Journal of Clinical Microbiology. 43: 4159-62. PMID 16081965 DOI: 10.1128/Jcm.43.8.4159-4162.2005 |
0.36 |
|
| 2005 |
López-Ribot JL. Candida albicans biofilms: more than filamentation. Current Biology : Cb. 15: R453-5. PMID 15964263 DOI: 10.1016/J.Cub.2005.06.020 |
0.442 |
|
| 2005 |
Ramage G, López-Ribot JL. Techniques for antifungal susceptibility testing of Candida albicans biofilms. Methods in Molecular Medicine. 118: 71-9. PMID 15888936 DOI: 10.1385/1-59259-943-5:071 |
0.499 |
|
| 2005 |
Ramage G, Saville SP, Thomas DP, López-Ribot JL. Candida biofilms: an update. Eukaryotic Cell. 4: 633-8. PMID 15821123 DOI: 10.1128/Ec.4.4.633-638.2005 |
0.318 |
|
| 2004 |
Ramage G, Tomsett K, Wickes BL, López-Ribot JL, Redding SW. Denture stomatitis: a role for Candida biofilms. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics. 98: 53-9. PMID 15243471 DOI: 10.1016/J.Tripleo.2003.04.002 |
0.424 |
|
| 2004 |
López-Ribot JL, Casanova M, Murgui A, Martínez JP. Antibody response to Candida albicans cell wall antigens. Fems Immunology and Medical Microbiology. 41: 187-96. PMID 15196567 DOI: 10.1016/J.Femsim.2004.03.012 |
0.329 |
|
| 2004 |
Ullmann BD, Myers H, Chiranand W, Lazzell AL, Zhao Q, Vega LA, Lopez-Ribot JL, Gardner PR, Gustin MC. Inducible defense mechanism against nitric oxide in Candida albicans. Eukaryotic Cell. 3: 715-23. PMID 15189992 DOI: 10.1128/Ec.3.3.715-723.2004 |
0.386 |
|
| 2004 |
Hernandez S, López-Ribot JL, Najvar LK, McCarthy DI, Bocanegra R, Graybill JR. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrobial Agents and Chemotherapy. 48: 1382-3. PMID 15047549 DOI: 10.1128/Aac.48.4.1382-1383.2004 |
0.362 |
|
| 2004 |
Carrillo-Muñoz AJ, Quindós G, Lopez-Ribot JL. Current developments in anti-fungal agents Current Medicinal Chemistry: Anti-Infective Agents. 3: 297-323. DOI: 10.2174/1568012043353766 |
0.361 |
|
| 2003 |
Bachmann SP, Ramage G, VandeWalle K, Patterson TF, Wickes BL, López-Ribot JL. Antifungal combinations against Candida albicans biofilms in vitro. Antimicrobial Agents and Chemotherapy. 47: 3657-9. PMID 14576141 DOI: 10.1128/Aac.47.11.3657-3659.2003 |
0.446 |
|
| 2003 |
Saville SP, Lazzell AL, Monteagudo C, Lopez-Ribot JL. Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection. Eukaryotic Cell. 2: 1053-60. PMID 14555488 DOI: 10.1128/Ec.2.5.1053-1060.2003 |
0.402 |
|
| 2003 |
Redding SW, Kirkpatrick WR, Saville S, Coco BJ, White W, Fothergill A, Rinaldi M, Eng T, Patterson TF, Lopez-Ribot J. Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation Journal of Clinical Microbiology. 41: 619-622. PMID 12574256 DOI: 10.1128/Jcm.41.2.619-622.2003 |
0.368 |
|
| 2002 |
Ramage G, Saville SP, Wickes BL, López-Ribot JL. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Applied and Environmental Microbiology. 68: 5459-63. PMID 12406738 DOI: 10.1128/Aem.68.11.5459-5463.2002 |
0.462 |
|
| 2002 |
Ramage G, VandeWalle K, Bachmann SP, Wickes BL, López-Ribot JL. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrobial Agents and Chemotherapy. 46: 3634-6. PMID 12384379 DOI: 10.1128/Aac.46.11.3634-3636.2002 |
0.438 |
|
| 2002 |
Bachmann SP, VandeWalle K, Ramage G, Patterson TF, Wickes BL, Graybill JR, López-Ribot JL. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrobial Agents and Chemotherapy. 46: 3591-6. PMID 12384370 DOI: 10.1128/Aac.46.11.3591-3596.2002 |
0.498 |
|
| 2002 |
Ramage G, VandeWalle K, López-Ribot JL, Wickes BL. The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. Fems Microbiology Letters. 214: 95-100. PMID 12204378 DOI: 10.1111/J.1574-6968.2002.Tb11330.X |
0.465 |
|
| 2002 |
Martinez M, López-Ribot JL, Kirkpatrick WR, Coco BJ, Bachmann SP, Patterson TF. Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole. Journal of Clinical Microbiology. 40: 3135-9. PMID 12202543 DOI: 10.1128/Jcm.40.9.3135-3139.2002 |
0.376 |
|
| 2002 |
Ramage G, Bachmann S, Patterson TF, Wickes BL, López-Ribot JL. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. The Journal of Antimicrobial Chemotherapy. 49: 973-80. PMID 12039889 DOI: 10.1093/Jac/Dkf049 |
0.466 |
|
| 2002 |
Bachmann SP, Patterson TF, López-Ribot JL. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. Journal of Clinical Microbiology. 40: 2228-30. PMID 12037093 DOI: 10.1128/Jcm.40.6.2228-2230.2002 |
0.382 |
|
| 2002 |
Perea S, López-Ribot JL, Wickes BL, Kirkpatrick WR, Dib OP, Bachmann SP, Keller SM, Martinez M, Patterson TF. Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrobial Agents and Chemotherapy. 46: 1695-703. PMID 12019078 DOI: 10.1128/Aac.46.6.1695-1703.2002 |
0.369 |
|
| 2002 |
Martínez M, López-Ribot JL, Kirkpatrick WR, Bachmann SP, Perea S, Ruesga MT, Patterson TF. Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis. The Journal of Antimicrobial Chemotherapy. 49: 515-24. PMID 11864952 DOI: 10.1093/Jac/49.3.515 |
0.389 |
|
| 2001 |
Ramage G, Wickes BL, Lopez-Ribot JL. Biofilms of Candida albicans and their associated resistance to antifungal agents American Clinical Laboratory. 20: 42-44. PMID 11570274 |
0.319 |
|
| 2001 |
Perea S, López-Ribot JL, Kirkpatrick WR, McAtee RK, Santillán RA, Martínez M, Calabrese D, Sanglard D, Patterson TF. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrobial Agents and Chemotherapy. 45: 2676-84. PMID 11557454 DOI: 10.1128/Aac.45.10.2676-2684.2001 |
0.358 |
|
| 2001 |
Ramage G, Walle KV, Wickes BL, López-Ribot JL. Biofilm formation by Candida dubliniensis Journal of Clinical Microbiology. 39: 3234-3240. PMID 11526156 DOI: 10.1128/Jcm.39.9.3234-3240.2001 |
0.495 |
|
| 2001 |
Ramage G, Vande Walle K, Wickes BL, López-Ribot JL. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms Antimicrobial Agents and Chemotherapy. 45: 2475-2479. PMID 11502517 DOI: 10.1128/Aac.45.9.2475-2479.2001 |
0.523 |
|
| 2000 |
Kirkpatrick WR, Lopez-Ribot JL, Mcatee RK, Patterson TF. Growth competition between Candida dubliniensis and Candida albicans under broth and biofilm growing conditions Journal of Clinical Microbiology. 38: 902-904. PMID 10655413 DOI: 10.1128/Jcm.38.2.902-904.2000 |
0.426 |
|
| 2000 |
Monteagudo C, Lopez-Ribot JL, Murgui A, Casanova M, Lajean Chaffin W, Martinez JP. Immunodetection of CD45 epitopes on the surface of Candida albicans cells in culture and infected human tissues American Journal of Clinical Pathology. 113: 59-63. PMID 10631858 DOI: 10.1309/Ljgn-V50B-Bhjp-Kytm |
0.326 |
|
| 1999 |
Redding SW, Zellars RC, Kirkpatrick WR, McAtee RK, Caceres MA, Fothergill AW, Lopez-Ribot JL, Bailey CW, Rinaldi MG, Patterson TF. Epidemiology of oropharyngeal Candida colonization and infection in patients receiving radiation for head and neck cancer Journal of Clinical Microbiology. 37: 3896-3900. PMID 10565903 DOI: 10.1128/Jcm.37.12.3896-3900.1999 |
0.345 |
|
| 1999 |
López-Ribot JL, Bikandi J, Millán RS, Chaffin WLJ. Interactions between Candida albicans and the Human Extracellular Matrix Component Tenascin-C Molecular Cell Biology Research Communications. 2: 58-63. PMID 10527893 DOI: 10.1006/Mcbr.1999.0152 |
0.329 |
|
| 1999 |
Lopez-Ribot JL, McAtee RK, Kirkpatrick WR, La Valle R, Patterson TF. Low levels of antigenic variability in fluconazole-susceptible and - resistant Candida albicans isolates from human immunodeficiency virus- infected patients with oropharyngeal candidiasis Clinical and Diagnostic Laboratory Immunology. 6: 665-670. PMID 10473514 DOI: 10.1128/Cdli.6.5.665-670.1999 |
0.372 |
|
| 1999 |
Lopez-Ribot JL, McAtee RK, Perea S, Kirkpatrick WR, Rinaldi MG, Patterson TF. Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus- infected patients Antimicrobial Agents and Chemotherapy. 43: 1621-1630. PMID 10390213 DOI: 10.1128/Aac.43.7.1621 |
0.38 |
|
| 1998 |
Lopez-Ribot JL, Mcatee RK, Lee LN, Kirkpatrick WR, White TC, Sanglard D, Patterson TF. Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis Antimicrobial Agents and Chemotherapy. 42: 2932-2937. PMID 9797228 DOI: 10.1128/Aac.42.11.2932 |
0.337 |
|
| 1998 |
Kirkpatrick WR, Revankar SG, McAtee RK, Lopez-Ribot JL, Fothergill AW, McCarthy DI, Sanche SE, Cantu RA, Rinaldi MG, Patterson TF. Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar Candida screening and susceptibility testing of isolates Journal of Clinical Microbiology. 36: 3007-3012. PMID 9738058 DOI: 10.1128/Jcm.36.10.3007-3012.1998 |
0.386 |
|
| 1998 |
Sepúlveda P, López-Ribot JL, Murgui A, Cantón E, Navarro D, Martínez JP. Candida albicans fibrinogen binding mannoprotein: expression in clinical strains and immunogenicity in patients with candidiasis. International Microbiology. 1: 209-216. DOI: 10.2436/Im.V1I3.42 |
0.345 |
|
| 1998 |
Chaffin WL, López-Ribot JL, Casanova M, Gozalbo D, Martínez JP. Cell Wall and Secreted Proteins of Candida albicans: Identification, Function, and Expression Microbiology and Molecular Biology Reviews. 62: 130-180. DOI: 10.1128/Mmbr.62.1.130-180.1998 |
0.304 |
|
| 1998 |
Martínez JP, Gil ML, López-Ribot JL, Chaffin WL. Serologic Response to Cell Wall Mannoproteins and Proteins of Candida albicans Clinical Microbiology Reviews. 11: 121-141. DOI: 10.1128/Cmr.11.1.121 |
0.324 |
|
| 1996 |
López-Ribot JL, Casanova M, Gil ML, Martinez JP. Common and form-specific cell wall antigens of Candida albicans as released by chemical and enzymatic treatments. Mycopathologia. 134: 13-20. PMID 8817937 DOI: 10.1007/Bf00437047 |
0.315 |
|
| 1996 |
López-Ribot JL, Gozalbo D, Sepúlveda P, Casanova M, Martínez JP. Preliminary characterization of the material released to the culture medium by Candida albicans yeast and mycelial cells. Antonie Van Leeuwenhoek. 68: 195-201. PMID 8572676 DOI: 10.1007/Bf00871815 |
0.317 |
|
| 1994 |
López-Ribot JL, Navarro D, Sepúlveda P, Nogueira JM, Casanova M, Martinez JP. A comparative study on cell wall antigens and cell surface hydrophobicity in clinical isolates of Candida albicans. Mycopathologia. 127: 1-13. PMID 7935734 DOI: 10.1007/Bf01104005 |
0.357 |
|
| 1994 |
Lopez-Ribot JL, McVay CS, Chaffin WL. Murine tissues exposed to cytotoxic drugs display altered patterns of Candida albicans adhesion Infection and Immunity. 62: 4226-4232. PMID 7927678 DOI: 10.1128/Iai.62.10.4226-4232.1994 |
0.34 |
|
| 1991 |
Lopez-Ribot JL, Casanova M, Martinez JP, Sentandreu R. Characterization of cell wall proteins of yeast and hydrophobic mycelial cells of Candida albicans Infection and Immunity. 59: 2324-2332. PMID 2050401 DOI: 10.1128/Iai.59.7.2324-2332.1991 |
0.318 |
|
| 1990 |
Martinez JP, Lopez-Ribot JL, Gil ML, Sentandreu R, Ruiz-Herrera J. Inhibition of the dimorphic transition of Candida albicans by the ornithine decarboxylase inhibitor 1,4-diaminobutanone: Alterations in the glycoprotein composition of the cell wall Journal of General Microbiology. 136: 1937-1943. PMID 2269870 DOI: 10.1099/00221287-136-10-1937 |
0.311 |
|
| 1990 |
Martinez JP, Gil ML, Casanova M, Lopez-Ribot JL, Garcia De Lomas J, Sentandreu R. Wall mannoproteins in cells from colonial phenotypic variants of Candida albicans Journal of General Microbiology. 136: 2421-2432. PMID 2079629 DOI: 10.1099/00221287-136-12-2421 |
0.322 |
|
| Show low-probability matches. |